Medicina
Departamento
Pharmacoeconomics and Outcomes Research Iberia
Pozuelo de Alarcón, EspañaPublicaciones en colaboración con investigadores/as de Pharmacoeconomics and Outcomes Research Iberia (16)
2024
-
Incidence of refractory CMV infection with or without antiviral resistance in Spain: A systematic literature review
Transplantation Reviews, Vol. 38, Núm. 1
-
The burden of disease and quality of life in patients with acute hepatic porphyria: COPHASE study
Medicina Clinica, Vol. 162, Núm. 3, pp. 103-111
2023
-
Selection of Quality Indicators for the Certification of Dermato-Oncology Units: The CUDERMA Project Delphi Consensus Study
Actas Dermo-Sifiliograficas, Vol. 114, Núm. 7, pp. 587-605
-
Selection of Quality Indicators for the Certification of Psoriasis Units: The CUDERMA Project Delphi Consensus Study
Actas Dermo-Sifiliograficas, Vol. 114, Núm. 10, pp. 865-883
2022
-
Cost-effectiveness analysis of using innovative therapies for the management of moderate-to-severe ulcerative colitis in Spain
Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 22, Núm. 1, pp. 73-83
-
Cribado dirigido del virus de la inmunodeficiencia humana en los servicios de urgencias en España: análisis de las consecuencias epidemiológicas y económicas
Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias, Vol. 34, Núm. 1, pp. 21-28
-
Epidemiologic and Economic Analysis of Rapid Antiretroviral Therapy Initiation with Bictegravir/Emtricitabine/Tenofovir Alafenamide in Spain
PharmacoEconomics - Open, Vol. 6, Núm. 3, pp. 415-424
2017
-
Cost-effectiveness and cost-utility analysis of apixaban versus dabigatran and rivaroxaban in the treatment and secondary prevention of venous thromboembolism
Pharmacoeconomics - Spanish Research Articles, Vol. 14, Núm. 1, pp. 7-18
2016
-
Análisis de coste-efectividad y coste-utilidad de ingenol mebutato versus diclofenaco 3% e imiquimod 5% en el tratamiento de la queratosis actínica en España
Actas Dermo-Sifiliograficas, Vol. 107, Núm. 6, pp. 498-508
-
Cost-effectiveness analysis of apixaban compared to low-molecular-weight heparins and Vitamin K antagonists for treatment and secondary prevention of venous thromboembolism
Farmacia Hospitalaria, Vol. 40, Núm. 3, pp. 187-208
2015
-
Budgetary impact analysis on funding smoking-cessation drugs in patients with COPD in Spain
International Journal of COPD, Vol. 10, Núm. 1, pp. 2027-2036
-
Cost effectiveness of lanthanum carbonate in chronic kidney disease patients in Spain before and during dialysis
Health Economics Review, Vol. 5, Núm. 1
-
Cost-effectiveness analysis of lanthanum carbonate versus sevelamer hydrochloride in the treatment of hyperphosphatemia in patients with end-stage renal disease in Spain
Pharmacoeconomics - Spanish Research Articles, Vol. 12, Núm. 1, pp. 11-22
-
Use of healthcare resources and costs of acute cardioembolic stroke management in the Region of Madrid: The CODICE Study
Neurologia, Vol. 30, Núm. 9, pp. 536-544
2012
-
Cost effectiveness of prostacyclins in pulmonary arterial hypertension
Applied Health Economics and Health Policy, Vol. 10, Núm. 3, pp. 175-188
2009
-
Infliximab maintenance therapy is associated with decreases in direct resource use in patients with luminal or fistulizing crohn's disease
Journal of Clinical Gastroenterology, Vol. 43, Núm. 10, pp. 950-956